Re Portfolio Company

RNS Number : 0518D

Frontier IP Group plc

24 April 2013

 



AIM: FIPP

Frontier IP Group Plc

("Frontier IP" or "the Group")

 

Portfolio Company Aridhia Announces Healthcare Research Collaboration

 

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to note the following announcement in relation to one of its portfolio companies, Aridhia Informatics Limited ("Aridhia"). The full text of Aridhia's announcement is set out below.

"Unique collaboration to drive groundbreaking healthcare research through Stratified Medicine Scotland Innovation Centre

Aridhia, academic, NHS and industrial partners to drive fusion of genomic and patient data to enable faster, more accurate clinical decisions.

Edinburgh, UK - 23 April, 2013 - Biomedical informatics company Aridhia today announced that it is a lead commercial partner alongside Life Technologies Corporation, a global biotechnology tools company, in the Stratified Medicine Scotland Innovation Centre (SMS-IC). The SMS-IC is set to bring together expertise from within Scottish industry, academia and the NHS to drive forward a new age of stratified medicine globally, with the aim of offering improved, personalised healthcare treatments, tailored to the genetics of individual patients.

"The Stratified Medicine Scotland Innovation Centre is a globally significant program to determine the future of healthcare in the 21st century and Aridhia is very proud to be part of it. With the cost of sequencing an individual's genome continuing to fall rapidly, we need to understand how to find and unlock the associations with clinical and patient data in order to improve diagnosis and to personalise the treatment of disease to the individual. Do this, and we can change the way in which healthcare is delivered forever," said Dr David Sibbald, CEO and Chairman of Aridhia.

"Aridhia will provide the biomedical informatics platform and expertise required to collect, manage and analyse the vast volume and diversity of data that is needed to realise the potential of stratified medicine, while Life Technologies will deliver the DNA sequencing technology required to drive discovery and genetic analysis. Together, the two companies can support the development of detailed patient records integrating genomic and clinical data in order to explore the complex relationships between biological pathways and drug response."

The Stratified Medicine Scotland Innovation Centre aims to build on recent advancements in biomedical research which have begun to identify why people with the same disease do not behave in the same way, and why treatments are more effective for some people than others.

Current methods of managing illness, with standardised, a one-size-fits all trial and error medications and treatment pathways, are not always fit for purpose. Combining and analysing an individual's detailed genomic data with more traditional patient information will enable a move away from standardised to targeted treatments for groups of patients most likely to benefit.

However, while single gene testing is currently available within the NHS, significant advances in stratified medicine are being hampered by the challenge around the interoperability, analysis and interpretation of the huge amounts of data created about each patient. Aridhia's sophisticated biomedical informatics technologies will provide the SMS-IC with the platform required to analyse these huge amounts of clinical, patient, imaging and genomic data and provide a comprehensive picture of factors affecting each patient's treatment and healthcare outcomes.

Sibbald continued: "By combining our expertise with that of our academic, clinical and commercial partners, the SMS-IC will support the creation of new knowledge to inform the delivery of quality healthcare across the world and create economic growth for Scotland."

The immediate aim of SMS-IC is to enable precision targeting of population subsets in order to demonstrate the benefit of stratification in clinical trials, with a series of projects commencing throughout 2013."

About Aridhia

Aridhia provides world leading biomedical informatics and analytic solutions to support stratified medicine and translational research, which will enhance understanding, diagnosis, prevention and treatment of chronic diseases. Aridhia believes that the integration and application of patient, clinical and genomic data represents a powerful opportunity to support clinical care across healthcare sectors, provide patients with the ability to take a more active role in their own care and provide information at a population level about disease trends, risk factors, impact of treatment and informed public health programmes. Working in close collaboration with experts in a clinical faculty model, Aridhia's multidisciplinary team provides a unique combination of expertise to address one of the world's most pressing health problems. Find out more at www.aridhia.com 

About Life Technologies

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum - scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.

Enquiries

Company website: www.frontierip.co.uk

Frontier IP Group Plc		T: 0131 220 9491
Neil Crabb, Chief Executive
Seymour Pierce (Nominated Adviser and Joint Broker)		T: 020 7894 7000
Mark Percy / Julian Erleigh, Corporate Finance
David Banks / Paul Jewell, Corporate Broking
Peterhouse Corporate Finance Limited (Joint Broker)		T: 020 7469 0935
Jon Levinson / Lucy Williams
Biddicks		T: 020 3178 6378
Katie Tzouliadis

 

END

 

 

NRAMMGZDVFNGFZM